Background: The aryl hydrocarbon receptor (AhR) and estrogen receptor (ER) regulate signaling pathways that influence tumor progression in hormone receptor-positive breast cancer. Compound A, a compound under investigation, exhibits anti-tumor activity in breast cancer cells, although the underlying molecular mechanisms remain unclear.
Objective: This study investigates whether the anti-tumor effects of Compound A are mediated through AhR alone or through interactions between AhR and ER.
Methods: Hormone receptor-positive breast cancer cells were treated with Compound A, MeBIO, Indirubin, estradiol (E2), or vehicle control. Subcellular fractionation was performed to isolate cytosolic, nucleoplasmic, and chromatin-bound fractions. Protein localization and expression of AhR and ER were evaluated by Western blotting.
Results: Optimization of fractionation and immunoblotting protocols enabled detection of AhR and ER across cellular compartments. Preliminary findings suggest ligand-dependent changes in receptor localization, providing insight into potential interactions between AhR and ER following Compound A treatment. Quantitative analyses are ongoing.
Conclusion: Characterizing the relationship between AhR and ER may clarify the mechanism of action of Compound A and advance our understanding of receptor signaling in hormone receptor-positive breast cancer, informing future targeted therapeutic strategies.
